BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

Source: Getty Images Improving survival rates for patients with sarcomatoid differentiation can be attributed to advances in immunotherapy, according to researchers. The overall survival rate at 5 ...

Overall survival was significantly better with the combination therapy, achieving 23.1 months versus 19.6 months with PHP alone. Combination therapy of percutaneous hepatic perfusion with immune ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis with antibody-drug conjugates, suggest two trials presented at ESMO 2025.

Since the first Breast Cancer Awareness Month initiatives kicked off 40 years ago, improvements have been made in treating ...